Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL9716604 | 1.00 | GSR (0.57) | GSRMMP2LTA4HPOLBKMT2A | |
| Ornithine Aketoglutarate SCHEMBL15539555 | 0.96 | GSR (0.50) | GSRMMP2LTA4HPOLBKMT2A | |
| Diphenylamine SCHEMBL593267 | 0.86 | GSR (0.67) | GSRMMP2LTA4HPOLBKMT2A | |
| Ornithine Aketoglutarate SCHEMBL11031186 | 0.84 | GSR (0.47) | GSRLTA4HPOLBKMT2ATDP1 | |
| Ornithine SCHEMBL11031187 | 0.84 | GSR (0.47) | GSRLTA4HPOLBKMT2ATDP1 | |
| Lysine SCHEMBL2473830 | 0.82 | GSR (0.49) | GSRMMP2LTA4HPOLBKMT2A | |
| Lysine SCHEMBL22684870 | 0.81 | GSR (0.54) | GSRMMP2LTA4HPOLBKMT2A | |
| Lysine SCHEMBL4305051 | 0.80 | GSR (0.57) | GSRMMP2LTA4HPOLBKMT2A | |
| Lysine SCHEMBL28214073 | 0.79 | GSR (0.91) | GSRMMP2POLBKMT2ATDP1 | |
| Cysteine SCHEMBL4970300 | 0.79 | PTGS1 (0.52) | MMP2LTA4HKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028658-A1 | ANTIBODY-DRUG CONJUGATES FOR REDUCING THE LATENT HIV RESERVOIR | NEW YORK BLOOD CENTER, INC. | 2018-02-01 | — | — | US | claimed |
| EP-2842575-B1 | Auristatin drug linker conjugates | SEATTLE GENETICS INC (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016133927-A1 | ANTIBODY DRUG CONJUGATES FOR REDUCING THE LATENT HIV RESERVOIR | NEW YORK BLOOD CENTER, INC. (US) | 2016-08-25 | — | — | WO | claimed |
| US-20180028658-A1 | ANTIBODY-DRUG CONJUGATES FOR REDUCING THE LATENT HIV RESERVOIR | NEW YORK BLOOD CENTER, INC. | 2018-02-01 | — | — | US | disclosed |
| EP-2842575-B1 | Auristatin drug linker conjugates | SEATTLE GENETICS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9463252-B2 | Auristatin drug linker conjugates | SEATTLE GENETICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2016133927-A1 | ANTIBODY DRUG CONJUGATES FOR REDUCING THE LATENT HIV RESERVOIR | NEW YORK BLOOD CENTER, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| EP-2842575-A1 | Auristatin drug linker conjugates | Seattle Genetics, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2265283-B1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140050746-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8609105-B2 | Auristatin drug linker conjugates | SEATTLE GENETICS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110020343-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2265283-A1 | AURISTATIN DRUG LINKER CONJUGATES | Seattle Genetics, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009117531-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020343-A1 | AURISTATIN DRUG LINKER CONJUGATES | AURKA, AURKC, AURKB | GSR 3767/4885MMP2 2420/4885LTA4H 4113/4885 |
| US-20140050746-A1 | AURISTATIN DRUG LINKER CONJUGATES | AURKA, AURKC, AURKB | GSR 3767/4885MMP2 2420/4885LTA4H 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.